Table 1.
Participant characteristics of eight participating African-American cohorts
| |
|
CARe cohorts |
|
|
|
|||
|---|---|---|---|---|---|---|---|---|
| FamHS | JHS† | CARDIA* | JHS-ARIC† | MESA | MESA Family/Air | GeneSTAR | GENOA | |
| N analyzed |
596 |
1066 |
671 |
322 |
1646 |
934 |
272 |
316 |
| CAC score > 0, n (%) |
330 (55.4%) |
419 (39.3%) |
108 (16.1%) |
224 (69.6%) |
726 (44.1%) |
388 (41.8%) |
111 (40.8%) |
214 (67.7%) |
| CAC score mean |
175.8 |
108.8 |
21.7 |
267.4 |
127.7 |
123.6 |
49.1 |
252.7 |
| CAC score, median (Q1, Q3) |
0.8 (0, 73.3) |
0 (0, 37.8) |
0 (0,0) |
41.5 (0, 260.7) |
0 (0, 53.2) |
0 (0, 40.2) |
0 (0, 16.0) |
37.4 (0, 266.6) |
| CAC Heritability (SE) |
0.33 (0.10) |
0.47 (0.17) |
- |
- |
- |
0.31 (0.08)‡ |
0 (n/a) |
0.26 (0.16) |
| Age, mean (range) |
54.1 (36–83) |
51.1 (36–90) |
44.5 (37–54) |
65.1 (57–80) |
62.2 (45–84) |
58.0 (39–91) |
51.2 (36–64) |
69.6 (56–85.5) |
| Sex, n (% male) |
202 (33.9%) |
408 (38.3%) |
244 (36.4%) |
87 (27%) |
745(45.3%) |
375 (40.4%) |
92 (33.8%) |
86 (27.2%) |
| Current Smoker, n (%) |
144 (24.2%) |
123 (11.5%) |
157 (23.5%) |
30 (9.3%) |
297 (18%) |
190 (20.5%) |
75 (27.6%) |
27 (8.5%) |
| Diabetic, n (%) |
149 (25.4%) |
145 (13.6%) |
69 (10.3%) |
77 (23.9%) |
263 (16%) |
137 (14.8%) |
50 (18.4%) |
105 (33.2%) |
| Hypertension, n (%)§ |
458 (76.9%) |
607 (56.9%) |
229 (34.1%) |
243 (75.5%) |
981 (59.6%) |
561 (60.4%) |
186 (68.4%) |
263 (83.2%) |
| Statin Users, n (%)§ |
60 (10.1%) |
95 (8.9%) |
14 (2.1%) |
53 (16.5%) |
241 (14.6%) |
193 (20.8%) |
58 (21.3%) |
- |
| Prevalent CHD, n (%) | 67 (11.2%) | 46 (4.3%) | 13 (1.9%) | 26 (8.1%) | 0 | 46 (4.%) | 0 | 7 (2.2%) |
*CARDIA: Year 20 data; hypertension by self-report.
† JHS CAC data comprised of the JHS de novo recruited sample “JHS” (n = 1066) and the JHS sample previously enrolled in the ARIC study, denoted “JHS-ARIC” (n = 322). CAC data were collected in all JHS participants (JHS and JHS-ARIC) through JHS NHLBI funding. The JHS-de novo recruited sample was genotyped as a batch via the CARe study at the Broad Institute. Genotyping of all AA ARIC participants also was performed as a separate batch via the CARe study at the Broad Institute. The recommendation from the CARe study analysis committee was to analyze the” JHS” and “JHS-ARIC” individuals separately because QC of JHS and ARIC genotype data was not 100% identical.
‡MESA Family/Air: heritability based on n = 882 in families from participants of MESA Family.
§GeneSTAR: hypertension = average of 3 measures ≥ 140/90 mmHg and/or current use of antihypertensive medication; GENOA: Self-reported hypertension. Statin use data was not available; MESA Family/Air: hypertension if diastolic > =90 or systolic > =140; or self-reported high blood pressure and on meds for hypertension; FamHS, CARDIA, MESA, JHS: hypertension = measure ≥140/90 mm Hg and/or current use of antihypertensive medication.